Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA EBITDA

EBITDA at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$25.58M+193%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$82.13M-13.5%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$82.36M-31.0%
LQD
Liquidia CorporationLQDA
$62M+277%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Calculated from Kiniksa Pharmaceuticals International, plc’s reported figures.

$29.3Mebit+
$468.0KDepreciation Depletion & Amortization
=$29.74M

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's EBITDA?
Kiniksa Pharmaceuticals International, plc (KNSA) reported EBITDA of $29.74M in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's EBITDA changed year-over-year?
Kiniksa Pharmaceuticals International, plc's EBITDA increased by 118.4% year-over-year, from $13.62M to $29.74M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's EBITDA?
Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's EBITDA has grown at a -15.5% compound annual growth rate (CAGR), from -$154.28M to $78.78M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.